Erratum: Role of activin-a and myostatin and their signaling pathway in human myometrial and leiomyoma cell function (The Journal of Clinical Endocrinology and Metabolism (2014) 99:5 (E775-E785) DOI: 10.1210/jc.2013-2623);Role of activin-A and myostatin and their signaling pathway in human myometrial and leiomyoma cell function

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages 1-2

  Islam, Md Soriful ^a,b   Catherino, William H ^c   Protic, Olga ^a   Janjusevic, Milijana ^a   Gray, Peter Clarke ^d   Giannubilo, Stefano Raffaele ^a   Ciavattini, Andrea ^a   Lamanna, Pasquale ^e   Tranquilli, Andrea Luigi ^a   Petraglia, Felice ^f   Castellucci, Mario ^a   Ciarmela, Pasquapina ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF RAJSHAHI   (Bangladesh)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^e Hospital Profili   (Italy)

^f UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; COLLAGEN; COLLAGEN 1A1; CYCLINE; FIBRONECTIN; KI 67 ANTIGEN; MESSENGER RNA; MYOSTATIN; SCLEROPROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; UNCLASSIFIED DRUG; VERSICAN;

ANTIGEN FUNCTION; ARTICLE; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MOLECULAR PATHOLOGY; MYOMETRIUM CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR CELL LINE; UTERUS MYOMA; WESTERN BLOTTING;

ACTIVINS; ADULT; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN TYPE I; FEMALE; FIBRONECTINS; HUMANS; LEIOMYOMA; MIDDLE AGED; MYOMETRIUM; MYOSTATIN; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS;

EID: 84899933946     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/clinem/dgz160     Document Type: Erratum

References (59)

1. Walker CL, Stewart EA. Uterine fibroids: The elephant in the room. Science. 2005;308:1589-1592.
2. Islam MS, Protic O, Toti P, et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab. 2013a;98:921-934.
3. Buttram VC Jr. , Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril. 1981;36:433-445.
4. Cramer SF, Patel A. The frequency of uterine leiomyomas.AmJ Clin Pathol. 1990;94:435-438.
5. Segars JH, Akopians AL. The two health disparities of uterine fibroids. Fertil Steril. 2013;99:1851-1852.
6. Peddada SD, Laughlin SK, Miner K , et al. Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci USA. 2008;105:19887-19892.
7. Laughlin SK Baird DD Savitz DA Herring AH Hartmann KE. Prevalence of uterine leiomyomas in the first trimester of pregnancy: an ultrasound screening study Obstet Gynecol. 2009 113 630.
8. Ciarmela P, Islam MS, Reis FM, et al. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update. 2011;17:772-790.
9. Islam MS, Protic O, Stortoni P, et al. Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertil Steril. 2013; 100:178-193.
10. Arici A, Sozen I. Tr ansforming growth factor-3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril. 2000;73:1006-1011.
11. Stewart EA, Friedman AJ, Peck K, Nowak RA. Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J Clin Endocrinol Metab. 1994;79:900-906.
12. Norian JM, Malik M, Parker CY, et al. Transforming growth factor-3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod Sci. 2009;16:1153-1164.
13. Leppert PC, Baginski T, Prupas C, CatherinoWH,Pletcher S, Segars JH. Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium. Fertil Steril. 2004;82(suppl 3): 1 182-1187.
14. CatherinoWH,Leppert PC, StenmarkMH,et al. Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chromosomes Cancer. 2004;40:204-217.
15. Malik M, Catherino WH. Development and validation of a threedimensional in vitro model for uterine leiomyoma and patientmatched myometrium. Fertil Steril. 2012;97:1287-1293.
16. Chegini N. P roinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med. 2010;28:180-203.
17. Chen YG, Lui HM, Lin SL, Lee JM, Ying SY. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med. 2002;227:75-87.
18. Luisi S, Florio P, Reis FM, Petraglia F. Expression and secretion of activin A: possible physiological and clinical implications. Eur J Endocrinol. 2001;145:225-236.
19. Tsuchida K, Nakatani M, Hitachi K, et al. Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signaling. 2009;7:15.
20. Li ZB, Kollias HD, Wagner KR. Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem. 2008;283:19371-19378.
21. Mukhopadhyay A, Chan SY, Lim IJ, Phillips DJ, Phan TT. The role of the activin system in keloid pathogenesis. Am J Physiol Cell Physiol. 2007;292:C1331-C1338.
22. Date M, Matsuzaki K, Matsushita M, Tahashi Y, Sakitani K, Inoue K. Differential regulation of activin A for hepatocyte growth and fibronectin synthesis in rat liver injury. J Hepatol. 2000;32:251-260.
23. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-family signalling. Nature. 2003;425:577-584.
24. Heldin CH, Miyazono K, Ten Dijke P. TGF-signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;465-471.
25. Shi Y, MassaguéJ. Mechanisms of TGF-signaling from cell membrane to the nucleus. Cell. 2003;113:685-700.
26. Ciarmela P, Wiater E, Vale W. Activin-A in myometrium: characterization of the actions on myometrial cells. Endocrinology. 2008; 149:2506-2516.
27. Ciarmela P, Wiater E, Smith SM, Vale W. Presence, actions, and regulation of myostatin in rat uterus and myometrial cells. Endocrinology. 2009;150:906-914.
28. Ciarmela P, Bloise E, Gray PC, et al. Activin-A and myostatin response and steroid regulation in human myometrium: disruption of their signalling in uterine fibroid. J Clin Endocrinol Metab. 2011a; 96:755-765.
29. Rhim JS. Generation of immortal human prostate cell lines for the study of prostate cancer. In Russell P, Jackson P, Kingsley EA, eds., Prostate Cancer Methods and Protocols. Springer, 2003 69-77
30. MalikM,WebbJ, CatherinoWH.Retinoic acid treatme nt ofhuman leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells. Clin Endocrinol (Oxf). 2008;69:462-470.
31. Shime H, Kariya M, Orii A, et al. Tranilast inhi bits the proliferation of uterine leiomyoma cells in vitro throughG1arrest associated with the induction of p21waf1 and p53. J Clin Endocrinol Metab. 2002; 87:5610-5617.
32. Islam MS, Protic O, Stortoni P , et al. Antiproliferative effect of tranilast on human myometrial and leiomyoma cells. Biol Biomed Rep. 2012;2:321-327.
33. Ciarmela P, Marzioni D, Islam MS, et al. Possible role of RKIP in cytotrophoblast migration: immunohistochemical and in vitro studies. J Cell Physiol. 2012;227:1821-1828.
34. Inman GJ, Nicolas FJ, Callahan JF, et al. SB-431542 is a potent and specific inh ibitor of transforming growth factor-superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002;62:65-74.
35. Draper LB, Chong H, Wang E, Woodruff TK. The uterine myometrium is a target for increased levels of activin A during pregnancy. Endocrinology. 1997;138:3042-3046.
36. Hayashi K, Carpenter KD, Gray CA, Spencer TE. The activin-follistatin system in the neonatal ovine uterus. Biol Reprod. 2003;69: 843-850.
37. Schneider-Kolsky M, Manuelpillai U, Gargett C, Wallace EM. Activin-A-subunit and activin receptors in human myometrium at term and during labour. BJOG. 2001;108:869-874.
38. Jones RL, Kaitu'u-Lino TJ, Nie G, Sanchez-Partida LG, Findlay JK, Salamonsen LA. Complex expression patterns support potential roles for maternally derived activins in the establishment of pregnancy in mouse. Reproduction. 2006;132:799-810.
39. Arici A, Sozen I. Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-1 in human myometrium and leiomyoma. Am J Obstet Gynecol. 2003; 188:76-83.
40. Tang XM, Dou Q, Zhao Y, McLean F, Davis J, Chegini N. The expression of transforming growth factor-s and TGF-receptor mRNA and protein and the effect of TGF-s on human myometrial smooth muscle cells in vitro. Mol Hum Reprod. 1997;3 :233-240.
41. Lee BS, Nowak RA. Human leiomyoma smooth muscle cells show increased e xpression of transforming growth factor-3 (TGF-3) and altered responses to the antiproliferative effects of TGF-. J Clin Endocrinol Metab. 2001;86:913-920.
42. Battegay EJ, Raines EW, Seifert RA, B owen-Pope DF, Ross R. TGF-induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 1990;63:515-524.
43. Joseph DS, Malik M, Nurudeen S, Catherino WH. Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor-3. Fertil Steril. 2010;93:1500-1508.
44. Wolanska M, Bankowski E. Transforming gro wth factor-and platelet-derived growth factor in human myometrium and in uterine leiomyomas at various stages of tumour growth. Eur J Obstet Gynecol Reprod Biol. 2007;130:238-244.
45. Chegini N, Luo X, Ding L, Ripley D. The expression of Smads and transforming growth factor-receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. Mol Cell Endocrinol. 2003;209:9-16.
46. Ding L, Xu J, Luo X, Chegini N. Gonadotropin releasing hormone and transforming growth factor-activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I col lagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab. 2004;89:5549-5557.
47. Levens E, Luo X, Ding L, Williams RS, Chegi ni N. Fibromodulin is expressed in leiomyoma and myometrium and regulated by gonadotropin-releasing hormone analogue therapy and TGF-through Smad and MAPK-mediated signalling. Mol Hum Reprod. 2005;11: 489-494.
48. Luo X, Ding L, Chegini N. CCNs, fibulin-1C and S100A4 expression in leiomyoma and myometrium: inverse association with TGF-and regulation by TGF-in leiomyoma and myometrial smooth muscle cells. Mol Hum Reprod. 2006;1 2:245-256.
49. Luo X, Ding L, Xu J, Chegini N. Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-. Endocrinology. 2005;146:1097-1118.
50. Ho J de Guise C Kim C Lemay S Wang XF Lebrun JJ. Activin induces hepatocyte cell growth arrest through induction of the cyclin-dependent kinase inhibitor p15INK4B and Sp1 Cell Signal. 2004 16 693-701.
51. Burdette JE, Jeruss JS, Kurley SJ, Lee EJ, Woodruff TK. Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res. 2005;65:7968-7975.
52. Kaneda H, Arao T, Matsumoto K, et al. Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer. Br J Cancer. 2011;105:1210-1217.
53. Ta ylor WE, Bhasin S, Artaza J, et al. Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am J Physiol Endocrinol Metab. 2001;280:E221-E228.
54. Langley B, Thomas M, McFarlane C, Gilmour S, Sharma M, Kambadur R. Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway. Oncogene. 2004;23:524-534.
55. Rogers R, Norian J, Malik M, et al. Mechanical homeostasis is altered in uterine leiomyoma. Am J Obstet Gynecol. 2008;198: 474.e1-474.e11.
56. Norian JM, Owen CM, Taboas J, et al. Characterization of tissue biomechanics and mechanical signaling in uterine leiomyoma. Matrix Biol. 2012;31:57-65.
57. Malik M, Segars J, Catherino WH. Integrin-1 regulates leiomyoma cytoskeletal integrity and growth. Matrix Biol. 2012;31:389-397.
58. David AC, Sam M, Nichole MB, William WH, Arnold IC. Proteoglycans of uterine fibroids and keloid scars: similarity in their proteoglycan composition. Bioche m J. 2012;443:361-368.
59. Leppert PC, Catherino WH, Segars JH. A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am J Obstet Gynecol. 2006;195:415-420.